Cuadro de texto: Volver a la pagina anterior

 

 

 

Cuadro de texto: Celiaquia y sobre-creciemiento bacteriano

 

 

Declaration of interest M.P. has received research funding from Laxdale Ltd, a company which is developing ethyleicosapentaenoic acid as a treatment for psychiatric and neurological disorders.

{dagger} See editorial, pp. 381–382, this issue

 

Cross-national differences in diet, the outcome of schizophrenia and the prevalence of depression: you are (associated with) what you eat{dagger}

Andrew McIntosh, MRCPsych and Stephen Lawrie, MRCPsych

Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh

Correspondence: Andrew McIntosh, Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh EH10 5HF,UK. Tel: +44 (0) 131 537 6671; e-mail: Andrew.mcintosh@ed.ac.uk

 

 


 

  Cuadro de texto: Abstract.- A peptide found in schizophrenia and autism causes behavioral changes in rats   Zhongjie Sun y J. Robert Cade University of Florida, USA Autism, Vol. 3, No. 1, 85-95 (1999)  In a previous study we showed that b-casomorphin-7 (b-CM7) is taken up by brain regions relevant to schizophrenia and autism. The present experiment was designed to find whether b-CM7 has any behavioral or analgesic effects in rats. About 65 seconds after treatment with different doses of b-CM7, rats became restless and ran violently, with teeth chattering and with rapid respiration. Seven minutes later, the rats became inactive with less walking, distancing themselves from the other rat in the same cage, and sitting in, or putting their head against, the corner of the cage. The sound response was reduced and social interaction was absent. One hour later, the rats showed hyperdefensiveness. The above behavioral effects of b-CM7 did not occur when rats were pretreated with naloxone (2 mg/kg, IP). The rats receiving saline did not show any behavioral changes throughout the 2 hour period of observation. b-CM7 also demonstrated analgesic effects, which could be blocked by naloxone. The results suggest that b-CM7 may play a role in behavioral disorders such as autism and schizophrenia. Celiac disease is a risk factor for schizophrenia John Hopkins Bloomberg School of Public Health People with a history of the digestive disorder celiac disease are three times more likely to develop schizophrenia than those without the disease, according to a report by Danish researchers and a researcher at the Johns Hopkins Bloomberg School of Public Health. The report is published in the February 21, 2004, edition of the British Medical Journal. (ver articulo completo en inglés) Abstract .- Neurological Deficits in Patients With Celiac Disease Adi Vaknin-Dembinsky, MD; Rami Eliakim, MD; Israel Steiner, MD Arch Neurol. 2002;59:647-648.  Para leer el texto completo debe inscribirse en la revista. haga clik en el título. Celiac disease (CD) is an autoimmune enteropathy triggered by the ingestion of gluten in genetically susceptible individuals.1 Developments in the understanding of the pathogenetic basis of the disease and the introduction of serological diagnostic markers have enabled the delineation of its epidemiological features and its clinical spectrum. This, in turn, has led to increased interest in the possible neurological manifestations and involvement in patients with this disorder. www.Schizophrenia.com    En Esta página web encontrará también el uso de la dieta como terapia conjunta. http://www.schizophrenia.com/treatments.htm#gluten La importancia de los ácidos grasos Omega-3 http://www.schizophrenia.com/treatments.htm#epa Abstract.- The neurology of gluten sensitivity: separating the wheat from the chaff. Wills AJ, Unsworth DJ.   Curr Opin Neurol. 2002 Oct;15(5):519-23. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis Background Dietary variations are known to predictthe prevalence of physical illnesses such as diabetes and heart disease but the possible influence of diet on mental health has been neglected. Aims To explore dietary predictors of the outcome of schizophrenia and the prevalence of depression. Method Ecological analysis of national dietary patterns in relation to international variations in outcome of schizophrenia and prevalence of depression. Results A higher national dietary intake of refined sugar and dairy products predicted a worse 2-year outcome of schizophrenia. A high national prevalence of depression was predicted by a low dietary intake of fish and seafood. Conclusions The dietary predictors of outcome of schizophrenia and prevalence of depression are similar to those that predict illnesses such as coronary heart disease and diabetes, which are more common in people with mental health problems and in which nutritional approaches are widely recommended. Dietary intervention studies are indicated in schizophrenia and depression. Introducción Some physical illnesses, particularly diabetes and coronary heart disease, occur with increased frequency in patients with schizophrenia and major depression (Peet & Edwards, 1997; Ryan & Thakore, 2002). These physical illnesses share some epidemiological features with mental disorders. Thus, the outcome of schizophrenia is generally better in developing countries than in more ‘developed’ nations (Hopper & Wanderling, 2000). Similarly, diabetes and heart disease are regarded as diseases of Western industrialised nations and are less common in developing countries (Tucker & Buranapin, 2001). It is well recognised that the pattern of food intake is of substantial importance in the aetiology of diabetes and heart disease. In view of the clinical and epidemiological association between these mental and physical illnesses, it is surprising that there has been little research interest in the relationship between nutrition and mental illness. The present study is an ecological analysis of international variations in food supply in relation to epidemiological data on the outcome of schizophrenia and on the prevalence of depression. Malcolm Peet, FRCPsych Swallownest Court Hospital, Aughton Road, Sheffield S26 4TH, UK. Correspondence: Tel: +44 (0)114 2872570; fax: +44 (0)114 2879147; e-mail: malcolmpeet@yahoo.com Declaration of interest M.P. has received research funding from Laxdale Ltd, a company which is developing ethyleicosapentaenoic acid as a treatment for psychiatric and neurological disorders. See editorial, pp. 381–382, this issue   Cross-national differences in diet, the outcome of schizophrenia and the prevalence of depression: you are (associated with) what you eat Andrew McIntosh, MRCPsych and Stephen Lawrie, MRCPsych Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh Correspondence: Andrew McIntosh, Division of Psychiatry, Royal Edinburgh Hospital, Edinburgh EH10 5HF,UK. Tel: +44 (0) 131 537 6671; e-mail: Andrew.mcintosh@ed.ac.uk